OptimizeRx Co. (NASDAQ:OPRX – Get Rating) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $19.20.
OPRX has been the topic of a number of recent analyst reports. Royal Bank of Canada decreased their price target on OptimizeRx from $22.00 to $18.00 and set an “outperform” rating on the stock in a report on Thursday, March 9th. SVB Leerink reissued an “outperform” rating on shares of OptimizeRx in a report on Friday, January 27th. William Blair reissued an “outperform” rating on shares of OptimizeRx in a report on Tuesday, March 21st. B. Riley cut their price objective on OptimizeRx from $30.00 to $28.00 in a research report on Thursday, March 9th. Finally, Lake Street Capital cut their price objective on OptimizeRx from $25.00 to $18.00 in a research report on Thursday, March 9th.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Captrust Financial Advisors grew its position in OptimizeRx by 248.8% in the second quarter. Captrust Financial Advisors now owns 1,287 shares of the company’s stock worth $35,000 after acquiring an additional 918 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in OptimizeRx in the first quarter worth about $52,000. UBS Group AG grew its position in OptimizeRx by 290.0% in the third quarter. UBS Group AG now owns 1,997 shares of the company’s stock worth $29,000 after acquiring an additional 1,485 shares in the last quarter. Avalon Trust Co purchased a new position in OptimizeRx in the first quarter worth about $29,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in OptimizeRx by 39.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,033 shares of the company’s stock worth $51,000 after acquiring an additional 853 shares in the last quarter. Hedge funds and other institutional investors own 80.45% of the company’s stock.
OptimizeRx Stock Up 4.6 %
OptimizeRx (NASDAQ:OPRX – Get Rating) last issued its earnings results on Wednesday, March 8th. The company reported $0.01 EPS for the quarter. The business had revenue of $19.70 million for the quarter, compared to the consensus estimate of $21.84 million. OptimizeRx had a negative return on equity of 9.27% and a negative net margin of 22.79%. As a group, equities analysts expect that OptimizeRx will post -0.68 EPS for the current year.
OptimizeRx Company Profile
OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support.
- Get a free copy of the StockNews.com research report on OptimizeRx (OPRX)
- monday.com Surges on Price and Volume after Blowout Results
- Can Ryanair Stock Fly Above Resistance Levels, What Earnings Show
- All Aboard! The Sell-Side Has Railroads In Reversal
- Is There Value Left in Lyft Stock?
- Everything About ZIM Integrated Screams Undervaluation
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.